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4ABSTRACT
1. A fully automated method was developed for lactate
dehydrogenase isoenzyme 1 (LD1) using 1,6-hexanediol
as chemical inhibitor of other LD isoenzymes and the
Cobas Bio centrifugal analyser.
2. The analytical performance of the established LD1
method was evaluated. The precision and accuracy of
this method were good. The linearity limit of LD1
measurement was up to 1000 U/1.
3. The interference study showed that a very high
triglyceride concentration falsely elevated the LD1
activity. Total LD measurement was not affected.
Haemolysis had a marked effect.on both total LD and
LD1 activities.
4. Stability studies showed that there was no
significant change of both total LD and LD1
activities after 48 hours storage at room
temperature and 4 Deg.C. All isoenzymes were stable
for 2 weeks stored at -70 Deg.C. There was loss of
activity in specimens stored at -20 Deg.C.
5. The established reference range of LD1 activity was
19- 101 U/1 (n= 106). The Ml/total LD reference
range was 0.04- 0.18.
6. For the diagnosis of acute myocardial infarction,
the efficiency of LD1 using a cutoff point of 3
times the upper limit normal (ULN) was 94%. Using
greater than or equal to 2 ULN as cutoff, the
efficiency of LDltotal LD ratio was 100%.
7. For the period from 12 hours to 72 hours after the
onset of cardiac symptoms, the LDltotal LD ratio
was found to be useful in detection of myocardial
infarction.
1. INTRODUCTION
1.1 Acute Myocardial Infarction
Acute myocardial infarction (AMI) is due to sudden
coronary artery occlusion causing ischaemia and
necrosis. The cardiac muscle cannot sustain its normal
function. Basically, there are two types of AMI:
transmural and subendocardial infarction. The former is
associated with atherosclerosis involving a major
coronary artery and the latter involves small areas
particularly the subendocardial wall of the left
ventricle and septum [1]. AMI is one of the clinical
manifestations of coronary artery diseases. The causes
of coronary artery disease are unknown, however, there
are several predisposing factors such as male sex, old
age, smoking, hyperlipidaemia and hypertension [2].
AMI is one of the most commonly diagnosed diseases in
hospitalised patients in Western countries. In United
States, there are about 1.3 million occurances of AMI
each year. Mortality during the first year after
infarction is about 50 percent [3]. From several British
surveys, it was shown that the incidence of AMI varied
with sex, social class and geographic region [4].
Mortality after AMI is high, particularly the first few
hours after the onset of cardiac symptoms. Furthermore,
there are two common complications that develop after
infarction, namely arrhythmia and pump failure [3].
Therefore, prompt, confirmation of diagnosis is crucial
for monitoring and management of patients with regards
to factors such as oxygen therapy, analagesia, and
anticoagulants given. The treatment may reduce mortality
due to arrhythmia and may minimize the size of
infarction, increasing the chance of survival.
1.2 Diacmosis Of Acute Mvocardial Infarction
The World Health Organisation has set up an
international criteria for the diagnosis of AMI [5] (see
Appendices 1- 3). The diagnosis of AMI is based mainly
on chest pain, electrocardiogram (ECG) abnormalities and
increased plasma enzymes such as lactate dehydrogenase
(LD), creatine kinase (CK) and aspartate transaminase
(AST) [6].
1.2.1 ECG
ECG is still the most definitive method for the
identification of AMI because of the specificity of new
QRS complex changes with elevation of the ST segment.
The QRS complex is a very sensitive indicator of new
infarction and it is the only ECG aspect considered to
be diagnostic. However, an equivocal ECG may be found
due to previous infarction, right bundle branch block
and left or right ventricular hypertrophy [6, 7, 8].
Therefore, the abnormal enzyme levels become important
in confirmation of the diagnosis.
1.2.2 Diagnostic Enzymes
After infarction, enzymes released from injured cells
enter into the blood circulation and thus raise the
plasma activity. The released enzymes have different
biological half-life in blood and thus exhibit a time
sequences of changes in plasma activity (Fig. 1) [9].
Initially, there is a lag phase of a few hours without
detectable elevation. Afterwards, plasma enzyme
activities become abnormal and rise quite sharply to a
peak before dropping back to normal. Therefore, the time
of blood sampling after infarction is crucial during
investigation. The routine enzyme measurements used for
investigation of AMI are total LD, total CK and AST
activities. However, the total activity may not be
heart-specific. Isoenzymes LD1 and CK-MB are more
heart-specific, therefore, they may be more useful in
assessing possible AMI [10].
Fig. 1 Enzymes Changes After Onset of Myocardial Infarction.
1.2.2.1 Asparate Amino-transaminase
(AST, EC 2.6.1.1)




The reaction equilibrium favours the backward reaction
and pyridoxal-5'-phosphate (P-5'-P) acts as a coenzyme.
There are different isoenzymes of AST distributed in
cytoplasm and mitochondria of cells. In case of minor
tissue damage, AST is mainly released from cytoplasm.
However, if cell necrosis occurs, released AST is mainly
from mitochondria. In practice, isoenzymes of AST are
not analysed separately [11].
AST is present in most tissue but especially in skeletal
and cardiac muscle, liver and kidney. Since AST
concentration is high in cardiac muscle, after
infarction, enzyme is released into the circulation. 6-8
hours after onset of chest pain, abnormal plasma AST
activity is detectable, and peaks at 18-24 hours, then
returns back to normal within 4-5 days. The peak value
is proportional to the size of infarction [11].
However, AST is not heart-specific. In pulmonary
infarction, hepatitis and hepatic congestion due to
heart failure, the plasma activity of AST is also
raised. In patients suffering from hepatitis, plasma
alanine aminotransferase (ALT) is higher than AST,
therefore the ratio ALTAST is greater than the normal
value of one. However, with cell necrosis such as in
AMI, considerable amounts of AST are also released and
the ALTAST ratio is decreased. Therefore, this ratio
helps to discriminate the origin of increased plasma
activity of AST [11].
1.2.2.2 Creatine Kinase and Isoenzymes
(CK, EC 2.7.3.2)





CK activity is greatest in striated muscle, brain and
cardiac muscle. It is a dimer of MW 40,000 consisting of
2 subunits, termed B and M. There are 3 isoenzymes: MM,
MB and BB. CK-BB predominates in brain and prostate; CK-
MM predominates in skeletal muscle and is present in
cardiac muscle; and CK-MB predominates in cardiac muscle
and is present in skeletal muscle [11].
In normal plasma, over 95% of the total CK activity is
due to CK-MM. After AMI, enzyme released from cardiac
muscle raise the plasma total CK activity, thus routine
measurement of the enzyme activity is performed for
diagnosis of AMI. However, an elevation may not be
heart-specific because muscle disease, strenuous
exercise and intramuscular injection may also increase
the plasma total CK activity [12].
CK-MB activity is heart-specific and is often used as a
diagnostic enzyme for AMI. It appears rapidly in plasma
after infarction, peaks in 10-24 hours and rapidly
declines within 2-4 days [9]. CK-MB is the most
sensitive indicator of AMI. However, proper sampling
times and frequent sampling are essential, otherwise
elevated plasma activity may be easily missed.
1.2.2.3 Lactate Dehydrogenase And Isoenzymes
(LD, EC 1.1.1.27)





The reaction equilibrium strongly favours the backward
reaction.
The enzyme has a molecular weight of 134,000 and is
composed of 4 polypeptide chains of 2 types, termed M
and H type, each under separate genetic control. By
different combination of subunits, there are five
isoenzymes. They are LD1(H4), LD2 (H3M), LD3 (H2M2), LD4
(HM3) and LD5 (M4) [11].
LD activity is present in almost all cells of the body.
Tissue activities are very high and any leakage from
tissue will significantly increase the plasma activity.
LD isoenzymes have different tissue distribution. LD1
and LD2 predominate in cardiac muscle, kidney and
erythrocytes whereas LD4 and LD5 predominate in liver
and skeletal muscle [11]. The activity of total LD in
plasma may be increased in a wide variety of diseases
such as AMI, megaloblastic anaemia, acute hepatic
disease and muscle disease. Thus total LD is not a
highly-specific test for AMI and heart-specific
isoenzymes LD1 and LD2 are used.
A study by Bruns et al in 1981 [13] demonstrated that
the LD1 to total LD ratio became abnormal before plasma
total LD activity was detected to be abnormal. The ratio
of LD1 to total LD had greater diagnostic value than LD1
alone. In 90% of AMI patients, this ratio was increased
within 12 hours of admission and 100% showed an
increased within 24 hours of admission. The false
positive rate was less than 1%. They commented the use
of flipped LD1LD2 ratio (ie LD1LD2) for the
diagnosis of AMI. However, this occured only as a late
event, one or more days after infarction and was not
observed at all in 15-20% of patients. Therefore, the
use of flipped ratio LD1LD2 was limited.
Conversely, the study of Jablonsky et al in 1985 [14]
showed that LD1LD2 ratio was an even earlier marker
than the LDltotal LD when onset of chest pain instead
of time after admission was used as the temporal
marker. Moreover, the ratio LD1LD2 did not have to be
flipped to be regarded as positive after myocardial
infarction. They also demonstrated that LD1LD2 ratio
became abnormal in most patients after AMI at the same
time as CK-MB.
In 1986, Adan et al [15] showed that the LDltotal LD
ratio in serum was superior to measurement of CK-MB, LD1
or both in the diagnosis of AMI. The ratio was most
valuable when interpretation of the results of CK-MB
isoenzymes was undertaken in patients with small or
slowly evolving AMI, on thrombolytic therapy, burns or
trauma, each of which affects the rate of appearance of
CK isoenzymes. Moreover, CK-MB activity had to be
frequently assayed at 6 hours intervals and LD1 could be
assayed 6 hours after the peak of plasma CK-MB activity.
Therefore the number of samples was reduced. The LD1
increased within 12 to 24 hours after the onset of
infarction and was correlated with the increase of CK-
MB. The main advantage of LD1 assay was that both the
increase of LDltotal LD ratio and the increased LD1
activity did not show the rapid decline seen with
CK-MB.
1.3 Measurement Of Heart-Specific LD Isoenzymes
Numerous methods are available to quantitate the heart-
specific LD isoenzymes activities. Principles .of these
methods are based on the physical properties, affinities
for substrate or inhibitors, and immunological
characteristics of the various isoenzymes. Some methods
can measure all 5 isoenzymes while others only measure
the heart-specific LD1 andor LD2.
1.3.1 Heat-Stabilitv
LD1 and LD2 isoenzymes are relatively stable to heating
at 60 Deg.C for 1 hour while LD4 and LD5 isoenzymes are
destroyed under these conditions. Thus the residual LD
activity of heat treated plasma is heart-specific. This
method is sensitive and specific but is rather time
consuming and the heating step also introduces
additional imprecision to the final result [9, 11].
1.3.2 Hvdroxybutvrate Dehydrogenase (HBDH) Activity
In this method, pyruvate is replaced by 2-oxobutyrate as
substrate for LD activity measurement. LD1 and LD2 have
relatively higher affinity for this substrate than LD4
and LD5 at low substrate concentration. Serum HBDH
activity therefore mainly reflects the presence of LD1
and LD2. However, at high substrate concentration, there
is no apparent discrimination between the affinities of
the different isoenzymes. The sensitivity and
specificity of HBDH in detecting AMI are only slightly
better than total LD measurement. Nevertheless, HBDH has
been widely used due to its convenience. [9]
1.3.3 Electrophoresis
Electrophoretic techniques are always used to measure
the individual LD isoenzymes. Because of charge
differences, the isoenzymes can be separated by
agarose, agar, cellulose acetate or polyacrylamide gel
with ionic buffer medium and then stained by
appropriate reaction. The staining procedure usually
involes the reduction of NAD with a tetrazolium salt
(nitro blue tetrazolium, NBT). Methyl phenozium
methosulphate is required as an intermediate carrier.
When reduced, the NBT forms an insoluble dark-blue
formazan which can be semi-quantitated by densitometry.
This method suffers from being a long and tedious
procedure. Skilled operator are often required to
achieve satisfactory results [9, 16].
1.3.4 Ion-exchange Chromatography
In 1978, Vasudevan et al [17] showed that the LD1
isoenzyme could be separated by ion-exchange column
chromatography using DEAE-sephadex and LD1 activity was
then measured. The technique is based on the interaction
of the different charges of the isoenzymes with the
column at a given pH followed by elution with stronger
buffer concentration. This is a time consuming process
and expensive columns are required. Furthermore, this
technique is also sensitive to temperature fluctation
which may affect the performance of the assay.
1.3.5 Immuno-inhibition Method
Ali et al [18] and Bruns et al [13] used immunochemical
methods to measure LD1 activity in patient samples. LD1
was separated using an antiserum against the M-subunit
which is present in all LD isoenzymes except LD1. The
antigen-antibody complexes were precipitated using a
second antibody. The supernatant was analysed for LD1
activity. This is a sensitive and specific method.
However, the antiserum reagents are very expensive.
1.3.6 Chemical Inhibition Method
There are chemicals which can selectively disrupt
protein structure in aqueous solution by altering the
secondary and tertiary structures. Tanishima et al [19]
in 1985 described a method for plasma LD1 which employed
a simple chemical compound, 1,6-hexanediol, as a
specific inhibitor of the LD M-subunit. The activity of
LD1 which is composed of the H-subunit only, was not
affected. Sodium perchlorate was used in a new
commercial LD1 reagent kit as a specific inhibitor of
the LD M-subunit similar to 1,6,-hexanediol [20]. These
chemical inhibitors provide the basis for a rapid and
cheap method for the determination of LD1 which can also
be adapted to automated analysis.
1.4. OBJECTIVES
The objectives of the present project are:
1. to establish a fully automated quantitative method to
measure the heart-specific LD1 isoenzyme activity in
plasma samples using 1,6-hexanediol as the chemical
inhibitor and the Cobas Bio Centrifugal Analyser, and
2. to evaulate the usefulness of the established method
in the diagnosis of AMI.
In this thesis, the establishment of a fully automated
method for measurement of LD1 using 1,6-hexanediol and
its analytical performance are presented. The reference
ranges for the total LD, LD1 and LDltotal LD ratio are
established in healthy individuals from the local
population. Finally, the usefulness of total LD, LD1 and
LDltotal LD ratio in the diagnosis of AMI is assessed.
2. MATERIALS AND METHODS
2.1 Development Of The Automated LD1 Assay
A chemical inhibitor solution of 3M was prepared by
dissolving 3.545 g of 1,6-hexanediol (M.W.=118)(Aldrich
Chemical Company, Milwaukee, WI, USA) in 1 ml of
deionized water. There was a marked volume expansion.
This solution was made up to volume with deionized water
in a 10 ml volumetric flask. Different working inhibitor
solution of 3.75M, 4.5M, 5M, 6M were similarly prepared
using 4.43g, 5.32g, 5.91g, 7.09g of the chemical
inhibitor, respectively.
High and low LD activity plasma pools were collected
from specimens received for measurement of cardiac
enzymes that were sent to Chemical Pathology Laboratory
at the Prince of Wales Hospital. These plasma pools were
used in subsequent experiments.
2.1.1 Protocol 1
(1) 200 ul of low LD activity plasma pool were pipetted
into 6 Cobas Bio sample cups and incubated in a
37 Deg.C water bath.
(2) 50ul of the different working inhibitor solutions
(3M, 3.75M, 4.5M, 5M, 6M) were pipetted into the
sample cups.
(3) The sample cups were vortexed and incubation was
continued for 15 min. The Behring Lactate (L P)
Dehydrogenase reagent (Behring Diagnostics, LA
Jolla, CA, USA) was prepared as recommended by the
manufacturer. Program 1 (Appendix 4) on the Roche
Cobas Bio analyser (Hoffmann Roche Diagnostica,
Basle, Switzerland) was started to pipette 6 ul of
the incubated mixture and 210 ul of Behring reagent
into the cuvettes. After a lag time of 2 min, the
rate of change of absorbance at 340 nm was
monitored. The enzyme activity in each cuvette was
calculated as the product of rate of change of
absorbance and the assigned CALCULATION FACTOR
(Parameter 2).
(4) Steps (1) to (3) were repeated for incubation times
of 12.5, 7.5, 5.0, 2.5 and 0 min. The sample for
the 0 min incubation time was processed by adding
50 ul normal saline to all sample tubes, instead
of the inhibitor solution.
(5) Steps (1) to (4) were repeated using the high LD-
activity plasma pool.
2.1.2 Protocol 2
(1) 800 ul of the low LD activity plasma pool were
pipetted into a test tube and incubated in a 37
Deg.C water bath for 10 min. 200 ul of 3M inhibitor
were pipetted into the test tube. The mixture was
vortexed and returned to the water bath. After 2.5
min, 100 ul of the mixture were pipetted into a
Cobas sample cup which was pre-cooled in an ice
bath to stop further inhibition. The incubated
mixture was sampled at 5.0, 7.5, 10.0, 12.5 and 15
min. LD activities in all samples were measured on
the Cobas Bio as described in protocol- 1.
(2) AO min incubation was performed by adding 200 ul
of normal saline instead of the inhibitor solution,
and the mixture was withdrawn immediately.
(3) Steps (1) and (2) were repeated using inhibitor
concentrations of 3.75M, 4.5M, 5.0M and 6.0M.
(4) Steps (1) to (3) were repeated using the high LD
activity plasma pool.
2.1.3 Protocol 3
(1) 12 ul of low LD activity plasma pool, 8 ul of
deionized water and 5 ul of 3M inhibitor solution
were pipetted into the cuvettes by the Cobas Bio
using program 2 (Appendix 4). The mixture was
incubated in the analyser for 2.5 min.
(2) After program 2 was completed, program 3 (Appendix
4) was activated to pipette 210 ul Behring (L P)
reagents into the cuvettes. The LD activity was
obtained as described in protocol 1.
(3) Steps (1) and (2) were repeated using
incubation times of 5.0, 7.5, 10, 12.5, 15 min by
changing the TIME INTERVAL (parameter 16) in
program 2 to 300, 450, 500, 750, and 900 s,
respectively.
(4) Steps (1) to (3) were repeated using inhibitor
concentrations of 3.75M, 4.5M, 5M and 6M. Normal
saline was used as blank.
(5) Steps (1) to (4) were repeated using the high LD
activity plasma pool.
2.1.4 Protocol 4
(1) The manufacturer's recommended reagent preparation
was used as reference to measure the total LD
activity.
(2) A modified Behring reagent was prepared by adding
3 ml of 3M inhibitor to the reagent vial which was
then made up to a final volume of 15 ml with
deionized water. The inhibitor solution was
therefore diluted five times giving a final
concentration of 0.6M.
(3) The low LD activity plasma pool was measured with
the modified Behring reagent on the Cobas Bio
using programme 1 (Appendix 4) as described in
protocol 1. Times of incubation, with the inhibitor
of 2.5, 5.0, 7.5, 10.0 and 15.0 min were performed
by varying the TIME OF FIRST READING (parameter
15).
(4) Steps (2) and (3) were repeated using different
inhibitor solutions with final concentrations of
0.75M, 0.9M, 1.0M, 1.2M.
(5) Steps (1) to (4) were repeated using high LD
activity plasma pool.
2.1.5 Protocol 5
Protocol 5 was similar to protocol 4 except that Roche
(P -L) LD reagent was used. The programming of the
Cobas Bio was modified to adopt the different reagent.
The inhibitor solution was similarly diluted with the
main reagent. Program 4 (Appendix 4) was started to
pipette 5 ul of sample, 45 ul deionized water and 190 ul
modified main reagent into the cuvettes and incubated
the reaction mixture for a time period designated by the
INCUBATION TIME (Parameter 13). 50 ul of a start
reagent containing pyruvate was then added to initiate
the LD reaction. Results were obtained as described in
protocol 1.
With this modification, the steps in protocol 4 were
repeated using the low and high LD activity plasma pools
and Gilford CKLD Isoenzymes Control (Ciba Corning,
Irvine, CA, USA) as samples.
2.2 Evaluation Of Analytical Performance Using
Protocol 5
The optimized conditions for LD1 measurement by this
automated method were established to be a final
inhibitor concentration of 1M and an incubation time of
10 min.
2.2.1 Precision
For within-batch precision, low and high LD activity
plasma pools were used to measure both total LD and LD1
activity. Gilford Commercial CKLD isoenzyme control was
used to assess the between-batch precision throughout
the experimental period of this project by measuring the
total LD and LD1 activities. Secondary controls were
also established by between-batch analysis of Roche N
and P plasma control.
2.2.2 Accuracy
2.2.2.1 Bv Comparison With Assayed Commercial Control
Commercially assayed Roche N and P controls and control
samples from the Wellcome Quality Assessment Program
cycles 32-1,32-2, 32-6 were used to measure the total LD
activity. The protocol 5 (600 s incubation time) and the
Roche recommended program (150 s incubation time) were
used. The results were compared with the assigned values
of the assayed controls and with the method group ranges
of the quality assessment program.
2.2.2.2 Correlation With Corning Electrophoresis
The total LD and LD1 activities were measured for
patient samples requesting routine cardiac enzyme
measurements. For the same samples, electrophoresis was
also performed as a reference method using Corning
electrophoresis colorimetric (blue) lactate
dehydrogenase isoenzyme set (Corning Medical, Palo Alto,
CA, USA). The kit instruction procedure was followed.
2.2.3 Linearity
From routine cardiac enzyme specimens, a high LD
activity plasma pool with an activity of approximately
4000 UL was obtained. Serial dilution by volume with
normal saline was performed to obtain values down to
1.25% of original activity. The total LD activity of the
diluted samples was measured to establish LD linearity.
High LD1 activity plasma pool (approximately 1000 UL)
was similarly prepared and serial volume dilution was
performed down to 1% of the original activity. The LD1
activity of the diluted samples was measured to
establish the LD1 linearity.
2.2.4 Interference
The effects of turbidity, icterus and hemolysis on the
measurement of total LD and LD1 activities were studied.
2.2.4.1 The Effect Of Turbidity
5- 50 ul of Intralipid (Kabivitrum, Stockholm, Sweden)
were added to 1 ml plasma. Total LD and LD1 activity
were measured. Triglyceride levels were measured on
Baker ENCORE centrifugal analyser using the standard
Baker Triglyceride reagent kit (Baker Instruments Corp.,
Allentown, PA, USA).
2.2.4.2 The Effect Of Bilirubin
Gilford paediatric bilirubin control was re-constituted
with one third of its intended volume( 1 ml) to obtain
the high bilirubin level of approximately 1000 umol1.
This was heated in 56 Deg.C water-batch for 30 min to
inactivate all LD activities. Serial dilution was
performed down to approximately 15 umol1. 20 ul of
different bilirubin solutions were added to 200 ul of
plasma sample and total LD and LD1 activities were
measured. 20 ul of water, instead of bilirubin solution,
was used as blank.
2.2.4.3 The Effect Of Haemolysis
Packed erythrocytes were washed twice with isotonic
magnesium chloride solution (Merck, Darmstadt, F.R.
Germany),and the supernatant was removed. To haemolyse
the red cells, the concentrated packed cells were frozen
at -70 Deg.C for 4 h and then thawed at room
temperature. The haemoglobin concentration in the
haemolysate was determined by Sysmex CC180 Cell Counter
(Toa Medical Electronics, Kobe, Japan) and found to be
27.6 gdl. Using saline, serial dilution down to 0.2
gdl was performed. 50 ul of haemolysate of different
haemoglobin concentration was added to 200 ul of plasma.
50 ul of water, instead of haemolysate, was used as
blank. Total LD and LD1 activities were measured.
Haemoglobin concentration in each sample was also
measured on the Cobas Bio using a cyanomethaemoglobin
in-house method. Total LD and LD1 activities in the
serial diluted haemolysates were measured.
2.3 Stability Study Of LD Activity
2.3.1 Storage At Room Temperature And 4 Deg.C
In routine practice at the Chemical Pathology
Laboratory, the Prince of Wales Hospital, some specimens
are stored for up to 48 h before analysis. This study
was done to investigate the effect on LD activity of 48
storage at room temperature and 4 Deg.C. Specimens
received for measurement of cardiac enzymes were divided
into 3 aliquots. In one aliquot, the total LD activity
was measured immediately. The other aliquots were
stored for 48 h at room temperature and 4 Deg.C before
analysis. The specimens were measured by the Baker
ENCORE centrifugal analyser using the standard Baker LD
reagent.
2.3.2 Storage At -20 Deg.C And -70 Deg.C
This was a cross-sectional study due to the limited
amount of plasma available. Specimens received for
measurement of cardiac enzymes were aliquoted into 3
cups. One aliquot was immediately analysed for total LD
and LD1 activities. The other two were stored at -20
Deg.C and -70 Deg.C. Seven specimens were analysed as a
batch after storage for 4 days, 1, 2, 4, 6 and 8 weeks.
For each specimen, total LD and LD1 activities were
measured on Cobas Bio and LD isoenzymes by the Corning
electrophoresis kit as previously described.
2.4 To Establish Reference Ranges For Total LP, LD1
And LDlTotal LP Ratio
2.4.1 Healthy Individuals
Venous blood was collected from healthy subjects and put
into 10 ml lithium heparin blood tubes. The blood tubes
were centrifuged for 5 min at 3000 rpm and the plasma
samples were collected and stored at -70 Deg.C for up to
2 weeks before analysis. There were 106 healthy subjects
including 66 males and 40 females. Among them 80%
subjects were medical students and the rest were healthy
technical staff and their relatives. The ages ranged
from 20 to 48 with a mean of 23 years old.
The total LD and LD1 activities were measured for all
specimens and the LDltotal LD ratio was calculated.
2.4.2 Out Patients With No Apparent Cardiac Disease
Plasma samples were selected from blood samples sent
from Li Ka Shing Specialist Clinic to the Chemical
Pathology Laboratory at the Prince of Wales Hospital.
These specimens were selected based on the clinical
details recorded on the request forms which showed no-
evidence of cardiac disease. Blood samples were
centrifuged for 5 min at 3000 rpm and the plasma samples
were collected for analysis. There were 54 out-patients
subjects, 26 males and 28 females. The ages ranged from
17 to 86 with a mean of 54 years old.
The total LD and LD1 activities were measured
immediately or within 48 h after storage at 4 Deg.C.
The LDltotal LD ratio was calculated.
2.5 To Establish The Usefulness Of LDlTotal LD Ratio
In The Diagnosis Of Acute Myocardial Infarction
2.5.1 Subjects
All patients suspected of AMI and who were admitted to
the coronary care unit (CCU) of the Prince of Wales
Hospital were included in the study. On admission, the
demographic data, the nature and time of onset of the
patient's cardinal symptom (chest pain or other) were
recorded on protocol form no. 1 (Appendix 5). Based on
the time of onset of symptoms, target sampling times for
the 12-lead ECG and plasma enzyme profiles were
calculated and filled in on the protocol form no. 2
(Appendix 6).
2.5.2 Specimens
An ECG and venepuncture for measurement of plasma tota
CK, CK-MB, total LD, LD1 and AST activities wer
performed at each of the following times:
1. On admission to CCU.
2. At the following time intervals following the onset
of chest pain, or other cardinal symptom:
(a) 12h+ 2h (10- 14h)
(b) 24h+- 4h (20 28h)
(c) 48h+- (40- 56h)
(d) 72h+- 8h (64- 80h).
(Note: if a sampling time was missed, the ECG or
venepuncture were performed as soon as possible
afterwards. The actual sampling times were recorded on
protocol form no. 1 and on the usual laboratory request
forms for all samples.)
5- 10 ml of heparinized blood was collected at each
sampling time and sent to the Chemical Pathology
Laboratory. Specimens were centrifuged for 5 min at 3000
rpm and plasma samples were collected. The samples were
stored at -70 Deg.C for up to 1 wk before analysis.
2.5.3 Diagnosis
The diagnosis of AMI was made on the basis of cardiac
symptoms, ECG and the classical cardiac enzyme assays
(total CK, total LD and AST), or at autopsy (see
appendice 1-3). All surviving subjects in whom a
definitive diagnosis of AMI had not been made underwent
a post-convalescence exercise thallium scan, except for
those who had evidence of a previous infarct.
2.5.4 Evaluation Of The Usefulness Of LD1 Measurement
In Detection Of Acute Myocardial Infarction
2.5.4.1 Upper Limit Of Normal
Results of enzyme activities in samples of suspected AMI
patients were converted into multiples of the upper
limit of normal (ULN) for ease of comparison. The value
was calculated by dividing the result by the upper limit
of its reference range. A result equal to the upper
limit of the reference range would therefore be termed
1 ULN; a result equal to three times the upper limit, 3
ULN.
2.5.4.2 Calculation Of Sensitivity, Specificity And
Efficiency Of The Tests
The specificity, sensitivity and efficiency were
determined for total LD, LD1, LD1total LD ratio, CK,
Encore-LD and AST. Sensitivity of a test is used to
characterize the incidence of true-positive (TP) results
obtained when a test is applied to patients known to
have the disease. Specificity of a test is used to
characterize the incidence of true negative (TN) results
obtained when a test is applied to subjects known to be
free of the disease. The efficiency of the test is
defined as the percentage of all results that are true
results, whether positive or negative.
It was decided that a relevant case could be established
if 3 or more samples were received from a patient
suspected of AMI. To calculate the sensitivity of a test
at 1 ULN, TP was assigned to a relevant case of AMI when
one or more samples had a test result greater then 1 ULN
and false negative (FN) was assigned when the test
results for all samples were less than or equal to 1
ULN. To calculate the specificity of a test at 1 ULN, TN
was assigned to a relevant case of non-AMI when the test
results for all samples were less than or equal to 1 ULN
and false positive (FP) was assigned when one or more
samples had a test result greater than 1 ULN, the
sensitivity, specificity and efficiency of the test were











TP+ FN +TN+ FP
x 100%
The calculations were then repeated using cutoff values
of greater then 2 ULN and 3 ULN.
2.5.4.3 Time Course Of Enzymes Changes
The test results were grouped according to the time
after onset of cardiac symptoms using 12 h intervals.
Both AMI and non-AMI results were plotted to examine the
time course of enzyme change.
3. RESULTS
3.1 Development Of The Automated LD1 Method
Protocols 1-4 used the Behring Lactate Dehydrogenase
reagent. These protocols were designed to establish a
fully automated LD1 method from a semi-automated version
(manual incubation with the inhibitor). The inhibitor
concentration and the time of incubation with the
inhibitor were optimized. Protocols 1-3 demonstrated
that the percentage of inhibition of the plasma pools
increased with inhibitor concentration as well as the
time of incubation. A typical pattern of inhibition is
shown on Fig. 2. However, protocol 4 showed an irregular
pattern and preliminary studies indicated that the
interaction of NAD and inhibitor in the incubation step
interfered with the subsequent measurement of residual
LD1 activity.
Protocol 5 used the Roche reagent which used the
reversed reaction (pyruvate to lactate) and the
substrate as a starter. This modification appeared to
eliminate the interference observed in protocol 4, since
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Fig. 2 Typical Inhibition Pattern of the LD Assay.
The optimum final inhibitor concentration in the main
reagent was found to be 1.0 M and the optimum incubation
time was 10 min.
3.2 Evaluation Of Analytical Performance Using
Protocol 5
3.2.1 Precision
The within-batch and between-batch precision of the
total LD and LD1 methods are shown in Table 1. The
precision of the automated method was acceptable.
3.2.2 Accuracy
3.2.2.1 Comparison With Assayed Control Values
The performance of the total LD assay with regards to
accuracy using the above established method and the
Roche recommended method are shown in Table 2. The
measured total LD activities were all within the the
assigned ranges. Furthermore, there was no significant
difference between the established and the Roche
recommended program on the Cobas Bio.
Table 1: Within-batch and Between-batch Precision
Performance of the Automated Total LD
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3.2.2.2 Correlation With Corning Electrophoresis Method
The correlation of the automated method using 1,6-
hexandiol and the Corning electrophoresis method for LD1
activity was good (Fig. 3). The correlation coefficient
was 0.991 and the equation for the regression after
Deming correction [22] was y=0.88x-15.5 (y denotes the
chemical inhibition method and x denotes electrophoresis
method). The correlation coefficient of the 2 methods
for LDltotal LD ratio was 0.872.
3.2.3 Linearity
The linearity of total LD and LD1 methods are shown in
Figs. 4 and 5, respectively. Total LD measurement was
linear up to at least 3500 Ul and LD1 measurement was
linear up to at least 1000 Ul. These limits were the
highest activities obtained from the pooled plasma.
3.2.4 Interference
3.2.4.1 The Effect Of Turbidity
The effect of turbidity on total LD and LD1 measurement
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Fig. 5 Linearity of LDl Activity.
Table 3. The Effect of Turbidity on the Automated


















































15.0 mmol1 had little effect on the total LD
measurement. However, at a triglyceride concentration
of 4.3 mmol1, the measured LD1 activity was 110% of the
original, and was 147% of the original at a triglyceride
concentration of 15 mmol1.
3.2.4.2 The Effect Of Bilirubin
The effect of bilirubin on total LD and LD1 measurement
is shown in Table 4. At bilirubin concentration below
65 umol1, there was an apparent increase of both
activities of less than 10%. However, higher bilirubin
concentrations were shown to cause a' significant
increase in the total LD and LD1 activities measured.
3.2.4.3 The Effect Of Haemolysis
Haemolysis showed a marked effect on the measurement of
both total LD and LD1 activities (Table 5). At a
haemoglobin concentration of 0.71 gdl, both total LD
and LD1 activities were increased to three times the
original activity. Table 6 shows that the haemolysate
itself contained very high total LD and LD1 activities,
thus haemolysate was contaminating the plasma samples
with the enzymes released from the red cells.
Table A. The Effect of Bilirubin on Total LD





















































Table 5. The Effect of Haemolysis on the Automated






































































3.3.1 Storage At 4 Deg.C And Room Temperature
After 48 h storage at room temperature and 4 Deg.C, the
total LD activity showed no significant change when
compared to the result of fresh samples (Table 7).
3.3.2 Storage At -20 Deg.C
The stability of total LD and the 5 isoenzymes after
storage at -20 Deg.C for up to 8 wk 'is shown on
Table 8. Total LD activity decreased slightly after 2 wk
The LD1 activity did not show a consistent pattern when
measured by the chemical inhibitor method. On the other
hand, the LD1 activity measured by the electrophoresis
method showed no decrease, but slight increase after 8
wk. Both LD2 and LD3 activities were stable for up to 6
wk of storage but decreased slightly after 8 wk. LD4
showed a definite decrease after 2 wk and LD5 was not
stable during storage at -20 Deg.C.
Table 7. Stability of Total LD Activity a
n_._ L..„_ .1_ i.. r-_~ r
M„„ .1„ .1 f„„ 1 ttA A„ J 1— K r(!
Storage meati SI
i-„ i..,
F r e s I
Room
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A D e g.(
7 7 1 17 9.9
281 173.0
262 166.0
Note: NS- by paired 'tf test
Table 8. Stability of LD Activity at -20 Deg.C










































































































Note: 1. C-LD1: by chemical inhibition, method
2. E-LD1 to E-LD5: by e1ectrophoretic method
3.3.3 Storaqe_At_-70 Peg.C
The stability of total LD and the 5 isoenzymes after
storage at -70 Deg.C for up to 8 wk is shown on Table
9. Total LD, LD1, LD2 and LD3 did not show a significant
decrease. LD4 began to decrease after 8 wk and LD5
decreased after 2 wk.
3.4 Reference Range
3.4.1 Healthy Individuals
The reference ranges obtained from 106 healthy
individuals for total LD, LD1 and LDltotal LD ratio are
shown in Table 10. The ranges for different sexes were
v
also determined. The reference ranges were calculated
using 2 methods: the population mean+- 2 standard
deviations (SD) and the 2.5- 97.5 percentiles. The
reference ranges for total LD showed a significant
difference between the two method of calculation. Fig.6
shows that the distribution of total LD results from the
reference population was skewed. Log transformation did
not improve the skewness. Thus, the range calculated
from the 2.5- 97.5 percentile was used as the reference
range. The male and female reference ranges for total LD
Table 9. Stability of LD Activity at -70 Deg.C
Mean 7. change of activity compared with fresh samples
TOTAL LD C-LD1 E-LD1 E-LD2 E-LD3 E-LD4 E-LD 5
































































































Note: 1. G-LD1: by chemical inhibition method
2. E-LD1 to E-LD5: by electrophoretic method
Table 10. Reference Ranges of Healthy Individuals













all 106 507 216 75-939 293-912 277- 1582
male 66 497 194 109-885 293-896 277- 1348
female 40 524 251 22-1026 279-912 279- 1582
all 106 56 23 10-102 19-101 2- 150
male 66 58 22 14-102 11-90 2- 117
female 40 55 26 3-10 7 10.-101 10- 105
all 106 0.11 0.035 0.04-0.18 0.04-0.18 0.01- 0.21
male 66 0.12 0.035 0.05-0.19 0.04-0.18 0.01- 0.20
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Fig. 6 Distribution of Total LD Activity in Healthy Individuals.
showed no significant difference. Therefore, the
established reference range for total LD was 293- 912
Ul, with no sex difference.
The reference ranges calculated for LD1 and LDltotal LD
ratio using the 2 methods showed agreement and the
distribution of LD1 results was Gaussian (Fig 7). There
was also no sex difference for LD1 and LDltotal LD
ratio. For consistency, the 2.5- 97.5 percentiles
method was used for total LD range, and the reference
ranges established were 19- 101 Ul for LD1 and 0.04-
0.18 for LDltotal LD ratio.
3.4.2 Out-Patients With No Apparent Cardiac Diseases
The reference ranges for total LD, LD1 and LDltotal
ratio obtained from out-patients with no apparent
cardiac diseases are shown in Table 11. The mean total
LD was 503 Ul which was similar to the population of
healthy individuals. Using the 2.5- 97.5 percentiles,
the calculated reference ranges were not different from
ranges described in 3.4.1.
LD 1 ACTIVITY
Fig. 7 Distribution of LD1 Activity in Healthy Individuals
by Chemical Method.
Table 11. Reference Ranges of Out-patients
with No Apparent Cardiac Disease













all 54 503 105 293-713 361-789 306- 816
male 26 482 87 308-656 361-626 361- 693
female 28 522 118 286-758 306-789 306- 816
all 54 57 23 11-103 18-109 18- 120
male 26 56 23 10-102 18-97 18- 109
female 28 58 24 10-106 18-103 18- 120
all 54 0.12 0.042 0.04-0.20 0.03-0.18 0.03-0.21
male 26 0.12 0.046 0.03-0.21 0.04-0.17 0.04- 0.21
female 28 0.11 0.038 0.03-0.19 0.03-0.18 0.03- 0.18
3.5 Evaluation Of The Usefulness Of LP Measurement
In Detection Of Acute Myocardial Infarction
3.5.1 Subjects
30 suspected AMI patients were included during the
experimental period and of these 18 were classed
relevant cases. 14 cases were diagnosed as AMI and 4
were non-AMI cases.
3.5.2 Sensitivity, Specificity And Efficiency Of
Different Tests
The sensitivity, specificity and efficiency of the
different enzyme measurements for detection of AMI when
using different cutoff limits are shown on Tables 12 and
13. Using the criteria of greater than either 2 ULN or 3
ULN, both LDltotal LD ratio and total CK showed 100%
efficiency.
3.5.3 Time Course Changes Of Total LP, LD1,
Activities And LDlTotal LD Ratio
The time course of changes of total LD, LD1 and
LDltotal LD ratio are shown in Figs. 8, 9 and 10.
Within the first 12 h after onset of cardiac symptoms,
many AMI cases had normal results. In the period 12-72 h
Table 12. Sensitivity, Specificity and Efficiency of
Total L D. LDl Activities and Their Ratio









































Table 13. Sensitivity, Specificity and Efficiency of
of Total CK, LD and AST
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Fig.£ Time Course Changes of Total LD Activity in
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Fig. 9 Time Course Changes of LDl Activity in Patients of
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Fig. 10 Time Course Changes of LD1Total LD Ratio in
Patients of Suspected Acute Myocardial Infarction.
no AMI patient specimen had a LDtotal LD ratio less
than 2 ULN (Fig. 10). The highest LD1 activity was more
than 6 ULN, the highest among the 3 tests (Fig. 9).
4. DISCUSSION
4.1 Development Of The Automated LD1 Method
Measurement of the heart-specific LD1 isoenzyme was
reported to be useful in the diagnosis of AMI [11,9]. In
1985, Tanishima et al [19] used 1,6-hexanediol as a
specific M-subunit inhibitor to measure plasma LD1 and
LD2 activities. Both the inhibitor and the enzyme
measurement steps were done manually. Later, Shamberger
[23] semi-automated the 1,6-hexanediol method using an
automated centrifugal analyser, with the inhibition step
done manually. A fully automated LD1 method is
preferrable in a routine laboratory because it should
have better precision, higher throughput and be less
labour intensive. Protocols 1-4 were designed to adapt
the 1,6-hexanediol method from a manual method to a
fully automated version in a logical fashion.
In protocol 1, the manual inhibition method of
Tanishima et al [19] was followed with LD1 activity
measured on the automated Cobas Bio centrifugal
analyser, although Tanishima et al measured it manually
by spectrophotometer. However, precision for duplicate
analysis was very poor, probably due to difficulties in-
manual pipetting of the viscous inhibitor solution and
in reproducing incubation times. Protocol 2 adapted
Shamberger's method [23] using an ice bath to stop the
inhibition after the appropriate time interval. The
incubation time was better controlled and precision of
replicate analysis was also improved.
To eliminate the manual inhibition step of the method,
protocol 3 was designed to make use of 2 programs on the
Cobas Bio. The first program was used for the
inhibition incubation and the second program was used to
measure the residual LD1 activity. This protocol
improved the pipetting of inhibitor solution. However,
the incubation time was not adequately controlled due to
differences in the time delay between the running of the
two programs, which caused variation in the actual
incubation time. The instrument could not start the
second program automatically which demanded the close
attention of the operator. This factor outweighed the
benefits of having an automated method.
A single reagent containing the inhibitor would be ideal
to solve the problems arising in protocol 3. Thus,
iprotocol 4 was attempted using the modified Behring
reagent containing the inhibitor. However, an irregular
pattern of inhibition was observed.
A preliminary investigation was carried out and
demonstrated that there was interaction of NAD with the
inhibitor in the incubation step. The degree of
interaction was related to the amount of inhibitor
present and resulted in increased absorbance at 340 nm,
probably due to conversion of NAD to NADH. There was no
apparent change in absorbance when NADH was incubated
with solutions of different inhibitor concentration.
This phenomenon was not reported by Tanishima et al [19]
and Shamberger [23] who were using a pyruvate to lactate
reaction in the measurement of LD activity (NADH—NAD).
In protocols 1-4, a lactate to pyruvate reaction was
used (NAD—NADH).
Fig. 2 shows the typical pattern of inhibition seen when
different amount of 1,6-hexanediol were incubated with
human pooled plasma samples. The percentage inhibition
increased with increasing concentration of inhibitor and
longer incubation time. Since the inhibition is a time-
dependent phenomenon, it is also possible that in
protocol 4 the measured LD activity represented a
complex summation of kinetics of the interaction of the
different isoenzymes with the substrate and the
inhibitor.
In protocol 5, the Roche reagent was chosen to overcome
the problems encountered in protocol 4. NADH was used in
the coupled indicator reaction and did not interact with
the 1,6-hexanediol. The substrate was added as a starter
after the inhibition incubation step. The reaction
conditions were similar to protocol 3 but all the
components were controlled by a single program on the
Cobas Bio. A typical inhibition pattern was obtained and
the precision of replicate analysis was the best among
the other protocols.
When comparing residual activity with inhibitor
concentration or incubation time no xplateau' of
activity was observed. This would indicate that all
other isoenzymes were inactive and that above a certain
concentration or time only LD1 activity remained. Thus,
there were no optimum values for inhibitor concentration
or incubation time. Also, a preliminary study using
electrophoresis demonstrated that the LD1 isoenzyme was
inhibited by high inhibitor concentration. These
observations indicate that 1,6-hexanediol may not be a
specific M-subunit inhibitor because it also acts on H-
subunit. Neither Tanishima et al [19] nor Shamberger
[23] reported the possible interaction of 1,6-hexanediol
with the H-subunit. Tanishima et al [19] indicated that
the inhibiton involved the entire LD molecule rather
than only the M-subunit.
The inhibitor concentration and incubation time chosen
for the automated LD1 method were decided empirically by
comparison with the electrophoresis results of the 21
samples. In this study, the inhibition conditions were
chosen to be a final inhibitor concentration of 1.0 M
incubated for 10 minute at 37 Deg.C. 0.75 M inhibitor
concentration and 15 minutes incubation time at 30 Deg.C
were used in Tanishima et al's study [19], while 0.9 M
and 5 minutes at 37 Deg.C were used in Shamberger's
study [23].
The established fully automated LD1 method has a fast
throughput. 28 samples can be measured within 15 minutes
compared to the electrophoresis method which takes 3
hours for 8 samples on one plate. The precision is
better than the manual electrophoresis method and the
reagent cost per test is HK$ 0.36 compared to HK$ 13.4
for the Corning electrophoresis method. This method is
suitable for use in a routine clinical chemistry
laboratory.
4.2 Evaluation Of Analytical Performance Using
Protocol 5
4.2.1 Precision
Although the same reagent and analyser were used for
the measurement of LD activities in the total LD and LD1
methods, the within and between-batch precision of the
total LD method was better than the LD1 method.This
might be due to the viscosity of the inhibitor solution
present in the main reagent for the LD1 method
introducing an additional source of imprecision during
reagent pipetting. In the study of Shamberger [23], the
within-batch CV of the LD1 method ranged from 8.2 to
9.4% and the between-batch CV from 5.5 to 9.7%. The
present automated method gave a within-batch CV of 3.4%
and a between-batch CV of 4.9 to 5.4%. The precision of
the fully automated LD1 method was better than
Shamberger's method [23], the additional imprecision
probably being introduced in the manual incubation step.
According to Young et al [24] the intra-individual
biological variation of total LD was found to have a
mean CV of 10%. Thus analytical precision of total LD
measurement should be targeted at a goal CV of less than
10%. The between-batch CV of the established total LD
method was 3% or less, which was better than the target
CV. According to the Wellcome Quality Assessment program
in 1986 [24], the cutoff point for the best 10%
laboratories for total LD had a precision CV of 3.5% or
less.
This author is not aware of any studies reported in the
literature on the biological variation of LD1. Thus, it
was not possible to evaluate the precision goal based on
biological variation. In the Australian Quality
Assessment Program, LD1 is included. According to the
Cycle 15 report, for the period ending in December 1987,
the best laboratory had a precision CV for LD1 of 3.1%,
and the best 20% laboratories had a precision CV of 5.8%
or less. The present established automated LD1 method
had a between-batch CV of 5.4% which is close to the
cutoff point of the best 20% laboratories.
4.2.2 Accuracy
Assayed Commercial Controls and samples from the
Wellcome Quality Assessment Scheme were used to assess
the accuracy of the total LD method. The results were
all within the appropriate ranges (Table 2). There was
no assayed commercial LD1 control available for accuracy
testing, therefore correlation with the electrophoretic
method was used for evaluation. The chemical and
electrophoretic LD1 (Fig. 3) and LDltotal LD ratio were
well correlated.
4.2.3 Linearity
The established linearity was up to 3500 Ul for total
LD and up to 1000 Ul for LD1. Difficulty was
experienced in obtaining very high total LD and LD1
activity from pooled plasma or from available commercial
control material. Since the same reagent was used, the
linearity of LD1 is expected to be similar to total LD.
This finding was similar to the linearity limit of 3600
Ul assigned by the reagent manufacturer. This linearity
limit was adequate for patient study because during the
experimental period only 3% of the samples had results
exceeding the limit and required dilution.
4.2.4 Interference
There was little effect of turbidity on total LD
activity with triglyceride level up to 15.0 mmol1,
indicating that the enzyme kinetic method was able to
overcome problems of turbidity. However, false elevation
of LD1 activity up to 47% was observed. Since increased
triglyceride concentration did not interfere with the
measurement of total LD activity, the interference in
LD1 method might result from the inhibition process.
High concentration of triglyceride might decrease the
inhibitor activity of 1,6-hexanediol and lead to falsely
high LD1 results. Therefore, very lipaemic plasma
samples are not suitable for the measurement of LD1
using the automated method.
There was little effect of bilirubin on both total LD
and LD1 activities below 65 umol1. However, there was
significant increase in measured activity with higher
bilirubin concentrations. This might be due to either
spectral interference or an incomplete inactivation of
LD activity in the bilirubin control materials. As
described in section 1.3.1, there might be residual,
heat-stable LD1 and LD2 activities in the bilirubin
control samples. Thus, when a larger volume of the heat
treated samples was used for higher bilirubin
concentration, this led to falsely high total LD and LD1
activities. Total LD and LD1 activities in the
bilirubin controls were not measured after heat
inactivation so the source of this interference could
not be identified.
There was marked effect of haemolysis on both total LD
and LD1 activities. High total LD and LD1 activities are
present in red blood cells [11]. The haemolysate study
(Table 6) also demonstrated that high total LD and LD1
activities were released from red cells. After
correction of the contamination from red cells, the
total LD and LD1 activities showed no significant change
with increased haemoglobin concentration. Therefore,
there was no spectral interference by haemoglobin.
However, grossly haemolysed specimens should be avoided
because at high haemoglobin concentration, the
absorbance of plasma samples could exceed the linearity
of the detector response in the spectrophotometer.
4.3 Stability Studies
One of the objectives of developing an automated LD1
method is to provide a simple and fast method for prompt
diagnosis of AMI. Thus, analysis of patient samples can
be performed with little delay. The stability study over
a period of up to 8 weeks performed at the beginning of
the investigations was primarily designed to examine
storage conditions so that reference samples and patient
samples could be stored and analysed in batches.
However, it also permitted investigation of the
stability of the individual isoenzymes stored at
different temperatures.
The routine practice in the Chemical Pathology
Laboratory at the Prince of Wales Hospital is to analyse
the cardiac enzymes specimens either freshly or within
48 hours after storage at 4 Deg.C. The study indicated
that there was no significant difference in total LD
activities in samples stored for 48 hours at both room
temperature and 4 Deg.C when compared with the total LD
activities in the same samples measured immediately.
Thus, specimens for the subsequent clinical study could
be analysed freshly or within 48 hours stored at 4
Deg.C. The total LD activity was stable for up to 4
weeks at -20 Deg.C and showed no significiant change
after 8 weeks at -70 Deg.C. In 1983., Shain et al [25]
found that there was no cryo-instability of LD
isoenzymes when heparinised plasma specimens were stored
at 2 to 4 Deg.C for 24 hours or at -90 Deg.C fgr up to
150 days. In 1986, Jacobs et al [26], found that there
was no significant decrease in total LD activity
after 6 weeks storage at -20 Deg.C. The order of
thermal stability was -20 Deg.C25 Deg.C 4 Deg.C with
approximately 87%, 74% and 53% of activity retained,
respectively. Furthermore, the heparinised plasma
specimens showed greater variability in LD stability
under different storage conditions than serum specimens.
Heparinised plasma was used in this study which may
account for the observed variation in stability of
stored specimens.
In this study, it was found that LD1 isoenzyme was
stable when stored at -20 Deg.C and -70 Deg.C. Jacobs et
al [26] also found that LD1 was stable for up to 45 days
under all the conditions studied. However, it was
commented that specimens for LD isoenzyme studies should
be stored frozen or at room temperature, but not at 4
Deg.C. This study also showed greater cryo-instability
of LD4 and LD5 isoenzymes than LD2 and LD3. Of the
isoenzymes, LD5 was the most labile. It was unstable at
-20 Deg.C and stable for only to 2 weeks at -70 Deg.C.
Storage at -90 Deg.C might improve the stability because
the study of Shain et al [25] showed that LD4 and LD5
activities were stable for up to 150 days at -90 Deg.C.
This study showed that specimens stored at -70 Deg.C
for up to 2 weeks are suitable for analysis of all LD
isoenzymes.
Due to a limited amount of cardiac enzymes plasma
samples and a limited supply of electrophoretic
materials, a cross-sectional design of stability study
was employed in this project. A longitidinal study has
the advantage of using the same sample thoughout the
study, minimizing the variation between samples which
affects a cross-sectional approach. On the other hand,
in a cross-sectional study, the different samples used
reflect more patient conditions and a broader spectrum
of isoenzyme composition.
4.4 Reference Range
Plasma sample were collected from 106 healthy
individuals to establish the reference ranges for total
LD, LD1 and LDltotal LD ratio. The sample size of the
study was not large and most of the subject were young
medical students (mean age 23). Therefore, application
of the ranges to the general population must be done
with caution. In practice, it was difficult to collect
plasma samples from healthy, older subjects because of a
general unwillingness to give blood.
The distribution of total LD activity was not Gaussian
(Fig. 6) and the log transformation did not improve the
situation. A non-Gaussian total LD distribution was also
illustrated in Werner's revivew article [27]. Similar
findings were also noted in establishing the total LD
reference range for the Prince of Wales Hospital( C.S.
Ho, personal communication). Using the 2.5-97.5
percentiles method, the reference range for total LD was
established to be 293- 912 Ul with no sex difference.
The reference range for the total LD activity
recommended by Roche is 211- 423 Ul, with no sex
difference. The reference range of 293- 912 Ul was
unexpectedly wide and quite different from the other
reference ranges for total LD using the same method.
The total LD activity of the reference samples may have
been affected by slight haemolysis.
The distributions of LD1 activity and LDltotal LD
ratio were more Gaussian and there were also no
differences between male and female reference ranges.
For consistency, the 2.5-97.5 percentiles were used and
the LD1 and LDltotal LD ratio reference ranges derived
were 19-101 UL and 0.04-0.18 respectively;In the study
of Jablonsky et al [14], the ULN for LD1 of 91 Ul was
similar to the range established here, although the ULN
for LDltotal LD ratio of 0.24 was slightly higher.
The established reference ranges were tested using
samples from out-patients with no apparent cardiac
disease. The ranges derived from these subjects were not
different (Table 11).
4.5 Evaluation Of The Usefulness Of LD Measurement In
Detection Of Acute Myocardial Infarction
To evaluate the usefulness of the automated LD1 method
in the detection of AMI, samples from 30 different
patients in CCU were collected. However, there were only
18 relevent cases for the determination of sensitivity
and specificity. The other 12 patients were not included
because there were less than 3 samples received from
each of them. Some patients died after one or two blood
samplings. In some cases, the clinical history available
for diagnosis was incomplete. In previous studies
dealing with a similar clinical situation, the
different groups used more patient cases. Ali et al [18]
reported a series of 100 cases and Bruns et al [13]
reported another series of 65 cases. In this study more
relevant cases would ideally be required to fully
evaluate the usefulness of the LD1 test. Nevertheless,
this series of 18 cases did demonstrate some patterns
similar to results obtained by the other groups.
For diagnosis of AMI, it is necessary to select a test
or test combinations which have the highest efficiency
because false negative and false positive findings are
equally undesirable [21]. The sensitivity, specificity
and efficiency of the different enzyme tests were
calculated from the 18 relevant cases (Tables 12 and
13). It should be emphasised that the patients had
already been admitted to the CCU and were thus a highly
selected group which influences the observed
sensitivity and specificity of the tests. Nevertheless
this situation is one in which these tests are often
applied. Using a cutoff limit of greater than or equal
to 2 ULN, the efficiency of LDltotal LD ratio and total
CK were 100%.
Bruns et al [13] concluded that the LDltotal LD ratio
had greater diagnostic value than the LD1 alone, with a
predictive value of 96% for AMI. Furthermore, the ratio
became positive for all infarcted patients during the
first 24 hours after admission, similar to the time span
for CK-MB elevation.
In this study, a LDltotal LD ratio of 0.36 (or 36%) was
used as the cutoff value and was shown to be 100%
efficient in diagnosis of AMI. This was similar to
Bruns et al's criteria of 40% as the cutoff point
[13]. Gordesky et al [28] used 27.5% as the cutoff
point but this resulted in a lot of false positive
findings.
The efficiency of LD1 alone was 89% at cutoff of 2 ULN
and 94% at 3 ULN (Table 12). Ali et al [18] showed that
the sensitivity and specificity of LD1 assay by an
immunochemical method (I-LD1) were 100% and 89%,
respectively, using the ULN of 90 Ul as cutoff point..
By an electrophoretic method (E-LD1), the sensitivity
and specificity of LD1 were 81% and 91%,
respectively. The diagnostic efficiency of the I-LD1 and
E-LD1 were 93% and 88%, respectively. Thus the
efficiency of LD1 in this study was comparable with that
of Ali et al [18].
With a LD1 of 100 Ul and a LDltotal LD ratio of 0.4 as
the cutoff limit, Weidner et al [29] showed that the
specificity of the tests combined was 93% and the
positive predictive value was 86%. However, in this
study, the two tests were considered separately.
The efficiency of total LD in diagnosis of AMI was not
satisfactory and decreased when the cutoff limits were
increased from 1 ULN to 3 ULN (Table 12). However, these
findings were likely to be affected by the established
reference range which could be falsely high due to
contamination by haemolysis.
The use of the heart-specific CK-MB isoenzyme in the
diagnosis of AMI was extensively studied [30, 31, 32].
It has been shown that there are changes in sensitivity
and specificity of CK-MB at various times after AMI and
that findings are method dependent. For example, the
sensitivity of CK-MB in detecting AMI varied from 11%
during the first 8 hours after onset of symptoms to 80%•
at 32 hours after infarction [32]. Therefore, it was
difficult to obtain a consistent cutoff point for use at
all time intervals. Galen et al [33] and Shahangian et
al [31] showed that the combined CK and LD isoenzymes
provided the highest efficiency in diagnosis of AMI.
Unfortunately, CK-MB results are not available for
comparison for this study.
This study showed that the LDltotal LD ratio and total
CK were equally efficient for diagnosis of AMI. However,
the half-life of total CK in plasma is shorter than that
of LD1 and total LD, and the LDltotal LD ratio is
abnormal for longer period [13]. Falsely high total CK
or CK-MB may be resulted from trauma to muscle or
intramuscular injection [10]. Therefore, use of the
LDltotal LD ratio is recommended.
The time course of changes of different enzymes are
plotted on Figs. 8, 9 and 10. The total LD activity
increased 12 hours after onset of cardiac symptoms and
reached 2 ULN after 24 hours. However, the total LD
might also be increased in other diseases and thus it
is not highly specific [13]. The LD1 activity and
LDltotal LD ratio also increased after 12 hours and
remained at higher levels, in accordance with Bruns et
al's findings [13]. Bruns et al [13] also showed that
the LDltotal LD ratio became abnormal before any
elevation of total LD activity was noted and the same
phenomenon was also observed in this study.
The temporal markers used in the different studies are
not consistent. Bruns et al [13], Bernstein et al [34]
and Gorkdesky et al [28] used time of admission and
Jablonsky et al [14] used onset of chest pain as
temporal markers for interpretation of the LD1 or
LDltotal LD ratio. Time of onset of cardiac symptoms
was used as the temporal marker in this study because it
was felt that this more closely reflected the real
starting point with regards to changes in plasma enzyme
activity. Furthermore, there were different time delays
between the onset of symptoms and the time .of admission.
It is recognised that the time of onset of cardiac
symptoms may often be poorly defined or unknown, but
this dilemma is unresolvable.
5. CONCLUSION
The established automated LD1 method is suitable to be
used in routine chemical pathology laboratory because of
its good precision, high throughput, and low reagent
cost when compared with other LD1 method and also
requires small sample volume. This provides an efficient
and economic means to measure LDltotal LD ratio in
patients suspected of AMI.
Aspects of the interaction of 1,6-hexanediol with both
the LD1 isoenzyme and NAD were discussed. Specific
experiments should be designed to confirm and
investigate the observed phenomena.
The LDltotal LD ratio is recommended for use in the
diagnosis of AMI because it has high efficiency and
remains abnormal for a longer period than total CK.
However, more relevant clinical cases are required to
fully evaluate the usefulness of this ratio.
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APPENDIX
Diaanostic criteria for a definite AMI
One or more of the following must be fulfilled:
1. An evolving diagnostic ECG (a minimum of 2
recordings), showing the development of pathological
Q waves (at least 3 0ms and 25% amplitude of the
followincr R wave).
2. A diagnostic ECG [the presence of either pathological
Q-waves or the combination of ST elevation and (in
the absence of ventricular conduction defects) T wave
depression], if no previous history of AMI or if
previous infarct changes in different ECG leads
PT.TT.Q
Positive enzymes. (See appendix 3.)
3. Prolonged cardiac pain (pain anywhere in the anterior9'
chest, left arm or jaw+- pain in the back,
shoulder(s), right arm or abdomen, the duration
exceeding 20 minutes)
PLUS
Positive enzymes. (See appendix 3.)
4. A positive autopsy diagnosis.
5. Positive exercise thallium scan in the absence of a
previous history of AMI
DT.TTQ
Positive enzvme. [See appendix 3.}
APPENDIX 2
Criteria for Exclusion of AM]
For the definite exclusion of AMI all of the following
criteria must be fulfilled (unless definitely excludec
at autopsy)
1. Absence of an evolvinc diacrnostic ECG
2. Absence of a diagnostic ECG of the first recordim
unless also one or more of the followinc:
(a) a previous history of AMI with documente
chances in the same leads:
(b) negative enzymes. (See appendix 3.)
3. Absence of positive enzymes. (See appendix 3)
4. Absence of equivocal egnzymes. (See appendix 3
TINTESS
Exercise thallium scan is negative.
R_ 'h5£irir,o -f nncifivp pyorr l cp l-hpi 11 inm cr?an lirilpsR
also one or more of the following:
(a) a previous history of AMI;
(b) negative enzymes. (See appendix 3)
APPENDIX:
Criteria for Positive Enzymes
Both plasma total CK and AST ULN (upper reference
limit for the normal population) within 48h+- 8h 000S
(of the onset of symptoms)
PLUS
Plasma total LD ULN within 72h+~ 8h 000S.
Peak plasma levels should be 2 x ULN for at least 2 c
the 3 enzymes.
Criteria for Equivocal Enzymes
Enzyme results which do not fulfil the ,criteria for
being positive but fulfil one or more of the
following:
1. Plasma CK-MBtotal CK ratio ULN within 48h+- 8h
000S
2. Plasma LD1LD ratio ULN within 72h+ 000S.
3. The occurance of two or more of the following:
(a) plasma total CK ULN within 48h+- 8h 000S
(b) plasma AST ULN within 48h+- 8h 000S
(c) plasma total LD ULN within 72h+- 8h 000S
Criteria for Negative Enzymes
Complete sets of enzyme results (i.e. results for all
the stipulated time intervals from 12h+- 2h after the
onset of symptoms) which are neither positive nor
equivocal.
Incomplete Enzymes
These are any set of enzyme results which do not fulfil
the criteria for being positive, equivocal or negative.
APPENDIX 4
Parameter Listing For Program 1,2,3 4
Proaram




3. Standard 1 Cone.
4. Standard 2 Cone.
5. Standard 3 Cone.
6. Limit
7. Temperature [DEG. C]
8. Type Of Analysis
9. Wavelength [NM]
10. Sample Volume [UL]
11. Diluent Volume [UL]
12. Reagent Volume [UL]
13. Incubation Time [SEC]
14. Start Reagent Volume [UL]
15. Time Of First Reading [SEC]
16. Time Of Interval [SEC]
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